GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Return-on-Tangible-Asset

EV Biologics (EV Biologics) Return-on-Tangible-Asset : -20.26% (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. EV Biologics's annualized Net Income for the quarter that ended in Dec. 2017 was $-8.96 Mil. EV Biologics's average total tangible assets for the quarter that ended in Dec. 2017 was $44.21 Mil. Therefore, EV Biologics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2017 was -20.26%.

The historical rank and industry rank for EV Biologics's Return-on-Tangible-Asset or its related term are showing as below:

YECO's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -39.47
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

EV Biologics Return-on-Tangible-Asset Historical Data

The historical data trend for EV Biologics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Return-on-Tangible-Asset Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Return-on-Tangible-Asset
18.41 17.57 12.42 -99.45 -22.69

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -391.08 -33.28 -646.22 - -20.26

Competitive Comparison of EV Biologics's Return-on-Tangible-Asset

For the Biotechnology subindustry, EV Biologics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where EV Biologics's Return-on-Tangible-Asset falls into.



EV Biologics Return-on-Tangible-Asset Calculation

EV Biologics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2017 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=-7.43/( (34.279+31.213)/ 2 )
=-7.43/32.746
=-22.69 %

EV Biologics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2017 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2017 )  (Q: Jun. 2017 )(Q: Dec. 2017 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2017 )  (Q: Jun. 2017 )(Q: Dec. 2017 )
=-8.956/( (31.213+57.206)/ 2 )
=-8.956/44.2095
=-20.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2017) net income data.


EV Biologics  (OTCPK:YECO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


EV Biologics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of EV Biologics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Updates on Funding and Sales

By ACCESSWIRE 10-02-2023

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021